The company that develops implantable neural interfaces in the human brain attracted the resources of ARK Invest, DFJ Growth, Founders Fund, G42, Human Capital, Lightspeed, QIA, Sequoia Capital, Thrive Capital, Valor Equity Partners, and Vy Capital on the ground of a 9 billion pre-money value.
Neuralink, the scaleup of Elon Musk for the development of implantable neural interfaces in the human brain, secured a 650 million US Dollars through a Series E financing round that ARK Invest, DFJ Growth, Founders Fund, G42, Human Capital, Lightspeed, QIA, Sequoia Capital, Thrive Capital, Valor Equity Partners, Vy Capital, and others joined (press release). Semafor said that Neuralink attracted such resources on the ground of a pre-money value of 9 billion. In April 2025, Bloomberg reported that the company was looking to raise 500 million for a pre-money value of 8.5 billion.
Peter Thiel’s Founders Fund led August 203 Series D round which was initially worth 280 million but increased of a further 43 million for a pre-money value of 3.5 billion (TechCrunch).
Neuralink will invest such resources in making its technology accessible to more people. The scaleup is already testing its technology on five persons with severe paralysis who are now using Neuralink to control digital and physical devices with thought. The scaleup also said it is going to start global clinical trials at major institutions for neurosurgical care such as Barrow Neurological Institute, Miami Project to Cure Paralysis – Miami University, University Health Network (Toronto Western Hospital), and Cleveland Clinic Abu Dhabi.
Neuralink is also pioneering new applications of the technology that go beyond digital device control and launched the CONVOY study. The US Government Agency Food and Drug Administration granted Neuralink with the innovative device designation for sight and speech restoration programs.
